US drug developer Vitae (Nasdaq: VTAE) has seen its share price soar after reporting successful results from its experimental psoriasis drug trial.
The stock nearly doubled in early trading, climbing 85.16% to $7.61 a share before closing up 65.21% at $6.79 a share in US trading yesterday.
Vitae announced this week that a Phase IIa proof-of-concept clinical trial had shown positive top line results on tests of VTP-43742, an oral medication with potential to treat multiple autoimmune disorders, including psoriasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze